Do you want to read an article? Please log in or register.
Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)
Central Nervous System TumorsLung, Respiratory and Thoracic Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Lung, Respiratory and Thoracic Cancer
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
N Engl J Med.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR
doi: 10.1056/NEJMoa1917346.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Eur J Cancer
Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Marco R, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G
doi: 10.1016/j.ejca.2021.02.005
Lung, Respiratory and Thoracic Cancer
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
J Immunother Cancer
Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S
doi: 10.1136/jitc-2020-001882
Lung, Respiratory and Thoracic Cancer
Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study
Lung Cancer.
Lang D, Horner A, Brehm E, Akbari K, Hergan B, Langer K, Asel C, Scala M, Kaiser B, Lamprecht B
doi: 10.1016/j.lungcan.
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
N Engl J Med.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group
doi: 10.1056/NEJMoa1716948.
Lung, Respiratory and Thoracic Cancer
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
Cancer Treat Rev.
Melosky B, Chu Q, Juergens RA, Leighl N, Ionescu D, Tsao MS, McLeod D, Hirsh V
doi: 10.1016/j.ctrv.2018.02.005.
Further Publications
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study
J Thorac Oncol
Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Zhou H, Wang S, Sun L, Puig O, Mancao C, Peng B, Fang W, Xu W, Zhang L
doi: 10.1016/j.jtho.2021.07.015
Lung, Respiratory and Thoracic Cancer
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer
J Thorac Oncol
Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS
doi: 10.1016/j.jtho.2021.06.019